Teva- Pharmaceutical Industries Ltd. TEVA

NYS: TEVA | ISIN: US8816242098   3/07/2025
17,01 USD (-0,23%)
(-0,23%)   3/07/2025

26 juni 2025 · Teva Releases Q2 2025 Aide Memoire · Persbericht

25 juni 2025 · Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025 · Persbericht

24 juni 2025 · Les données définitives de l’étude PEARL menée par Teva en conditions réelles confirment l’efficacité à long terme d’AJOVY® (frémanézumab) pour la prévention de la migraine chronique et épisodique · Persbericht

23 juni 2025 · Final Data from Teva’s PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY® (fremanezumab) for the Prevention of Chronic and Episodic Migraine · Persbericht

16 juni 2025 · Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology · Persbericht

3 juni 2025 · Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer · Persbericht

3 juni 2025 · Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maximum Amount and Election of Early Settlement · Persbericht

31 mei 2025 · New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025 · Persbericht

31 mei 2025 · Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-'749 (olanzapine) to Date · Persbericht

29 mei 2025 · Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day · Persbericht

27 mei 2025 · Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA · Persbericht

27 mei 2025 · Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in June · Persbericht

27 mei 2025 · Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma · Persbericht

22 mei 2025 · Teva Announces Increase of the Maximum Tender Amount of its Debt Tender Offer and Increases to Pool Tender Caps for Pool 2 Notes and Pool 3 Notes · Persbericht

20 mei 2025 · Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt · Persbericht

20 mei 2025 · Fitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Growth Strategy · Persbericht

19 mei 2025 · Teva Announces $2,000,000,000 (Equivalent) Debt Tender Offers For Notes Due 2026-2031 · Persbericht

19 mei 2025 · Teva Announces Launch of $2,000,000,000 (Equivalent) Offering of Senior Notes · Persbericht

16 mei 2025 · Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy · Persbericht

12 mei 2025 · Teva’s 2024 Healthy Future Report Highlights Sustainability Progress, Including Surpassed Targets Linked to Financial Strategy · Persbericht

Mijn selecties